Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating promising health innovations, today announced that its acquisition target, Evofem Biosciences, ...
The Pearsanta’s MET diagnostic test uses a blood-based biomarker for detecting mitochondrial DNA for diagnosing endometriosis ...
Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating promising health innovations, today announced that its majority-owned subsidiary, Pearsanta, ...
Under the Agreement, Evofem and Pearsanta will collaboratively develop a comprehensive go-to-market strategy and MET commercial plan ahead of the planned U.S. launch in mid-2025. To date ...
In tandem with this financing arrangement, Aditxt has also invested in Evofem Biosciences (OTC:EVFM), Inc., purchasing 260 shares of Series F-1 Convertible Preferred Stock for $260,000.
In tandem with this financing arrangement, Aditxt has also invested in Evofem Biosciences (OTC:EVFM), Inc., purchasing 260 shares of Series F-1 Convertible Preferred Stock for $260,000. This ...
Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024 Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the ...
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. Its commercial product is ...
Under the Second Amendment, the parties have extended the dates by which Aditxt shall complete the remaining $3 million in funding to Evofem through the purchase of 3,000 shares of Evofem’s F-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback